Bold claim first: a pivotal clash over vaccine safety and regulatory method reveals deep fault lines at the FDA. A recent memo from Vinay Prasad, the FDA’s chief medical and scientific officer and lead vaccine regulator, sparked an extraordinary leak and immediate controversy. In his note to staff, Prasad asserted—without presenting supporting evidence—that COVID-19 vaccines have caused the death of ten children in the United States. He then proposed sweeping, unilateral changes to how the agency regulates and approves vaccines, including seasonal flu vaccines, signaling a shift away from established practices.
Shortly after, twelve former FDA commissioners—together guiding the agency for more than three decades—bundled their response into a formal rebuttal published in the New England Journal of Medicine. They described Prasad’s memo as deeply troubling, portraying it as a threat to the FDA’s mission and, potentially, to public health. The open letter represents a rare, unified voice from regulators who question the direction of current policy.
Prasad’s memo targets the FDA’s existing update framework for vaccines like the annual flu shot and COVID-19 vaccines. The agency currently relies on immunobridging studies—research that compares immune responses to determine efficacy in new vaccine versions. Prasad dismisses this approach as inadequate and advocates for costly randomized trials, arguing updates would thus require months to years to complete.
The memo also includes a pressure-filled stance toward dissent: staff who disagree are urged to consider resigning, and expressing concerns is labeled as unethical or illegal. The former commissioners, however, stand with a different view. They describe Prasad’s proposals as part of a troubling sequence of changes at the FDA and criticize the plan as incoherent. They argue that Prasad’s criticisms of immunobridging mischaracterize both the scientific evidence and the regulatory history, particularly for vaccines that target well-understood pathogens through established mechanisms of action.
This dispute highlights a broader debate about how modern vaccines should be evaluated and updated in a world of rapid scientific progress and urgent public health needs. It raises questions about the balance between rigorous, time-tested regulatory science and the agility needed to respond to evolving viral threats. What do you think: should the FDA stick with immunobridging as a standard for updating vaccines, or is there a justified case for accelerating trials in certain situations? Share your perspective in the comments.
